Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

11.62 +0.04 (+0.39%)
Streaming Delayed Price Updated: 3:06 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >
News headline image
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices ↗
CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions. 
Via Benzinga
Topics Lawsuit
News headline image
Amneal to Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Outlook For Amneal Pharmaceuticals ↗
 
Via Benzinga
News headline image
What's Next: Amneal Pharmaceuticals's Earnings Preview ↗
 
Via Benzinga
News headline image
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts ↗
Amneal Pharmaceuticals Q3 sales rose 13% to $702.47 million, beating estimates. EPS hit $0.16, above consensus, driven by strong launches and specialty growth. 
Via Benzinga
News headline image
Amneal Reports Third Quarter 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal to Report Third Quarter 2024 Results on November 8, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire
News headline image
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability ↗
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
Via Benzinga
News headline image
Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗
AMRX stock results show that Amneal Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Amneal Reports Second Quarter 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal to Report Second Quarter 2024 Results on August 9, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
From Kashiv BioSciences, LLC
Via Business Wire
News headline image
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Releases 2023 Environmental, Social and Governance Report
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
3 Stocks to Buy That Are Up 100% Over the Past 52 Weeks ↗
Here are three stocks to buy up 100% in the past year. Make sure you add these to your portfolio so that you can reap the benefits. 
Via InvestorPlace
News headline image
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
From Amneal Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.